BRIEF-Cytokinetics Announces Positive Topline Results From Acacia-Hcm, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

0.00

May 5 (Reuters) - Cytokinetics Inc CYTK.O:

  • CYTOKINETICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM ACACIA-HCM, THE PIVOTAL PHASE 3 CLINICAL TRIAL OF AFICAMTEN IN PATIENTS WITH NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

  • CYTOKINETICS INC - ACACIA-HCM MEETS DUAL PRIMARY ENDPOINTS IN KCCQ-CSS AND MAXIMAL EXERCISE PERFORMANCE AT WEEK 36

  • CYTOKINETICS INC - NO NEW SAFETY SIGNALS IDENTIFIED; COMPLETION RATES SIMILAR FOR AFICAMTEN AND PLACEBO

Source text: ID:nGNX8tfgQ0

Further company coverage: CYTK.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.